1. HBW Insight
  2. >>Leadership

Would An Independent Analysis Of US FDA's Pandemic Response Find Transformative Effect?

Group of outside experts could help the agency determine the pandemic-inspired practices and regulatory changes to keep, former commissioner von Eschenbach says.

Screenshot from FDLI Annual Conference of former commissioners' discussion
Former FDA commissioners Andrew von Eschenbach, top left, Robert Califf, bottom left, and Mark McClellan, bottom right, discuss how the pandemic changed the agency with FDLI president and CEO Amy Comstock Rick. • Source: FDLI annual conference screenshot

A former US Food and Drug Administration commissioner, Andrew von Eschenbach, suggests an external group may offer the best chance for the agency to determine the best lessons learned by lessons from the coronavirus pandemic.

During an 18 May Food and Drug Law Institute Annual Conference session, von Eschenbach, president of Samaritan Health Initiatives, said the agency should use its coronavirus response to enhance its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 
• By Malcolm Spicer

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

More from HBW Insight

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By Tom Gallen

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

CHPA Navigates Trump Administration’s ‘Mixed Messages,’ Ready To Traverse DSHEA Changes

 
• By Malcolm Spicer

Some changes the administration has proposed are a “great example of regulating by press release,” says Duffy MacKay, CHPA’s dietary supplements chief. But “after 30 years, the Dietary Supplement Health and Education Act could be modernized to serve the consumer better.”

Alliance Pharma’s New Owners Will Instill ‘More Consumer-Oriented Mindset’

 
• By Tom Gallen

Private equity firms now in control of Alliance Pharma weighing úp plan to offload Rx business to help finance strategy to drive up sales and growth.